Novo Nordisk Sues Hims & Hers; TrumpRx Is Here; Physicians Are Not ‘Providers,’ Says ACP – Morning Medical Update Weekly Recap

Why It Matters

The lawsuit could reshape how telehealth companies source GLP‑1 therapies, while TrumpRx’s design may limit its effectiveness in reducing overall drug spend. ACP’s terminology shift aims to reinforce the fiduciary nature of physician‑patient relationships, influencing policy and public perception.

Key Takeaways

• Novo Nordisk sues Hims & Hers over compounded semaglutide
• Lawsuit cites patent infringement, FDA bypass, patient deception
• TrumpRx launches as coupon clearinghouse, excludes government plans
• ACP urges dropping “provider” term for physicians, promotes “clinician”

Pulse Analysis

The GLP‑1 market has become a flashpoint for both innovation and litigation. During the 2024‑2025 shortage of Wegovy and Ozempic, compounding pharmacies and telehealth platforms filled a critical gap, offering lower‑cost alternatives that bypassed traditional FDA approval pathways. Novo Nordisk’s legal action against Hims & Hers signals a strategic move to protect its patent portfolio and reassert control over the supply chain now that the FDA reports adequate availability. Industry observers anticipate that the case could set precedent for how digital health firms manage off‑label compounding, potentially prompting stricter regulatory oversight and reshaping telehealth business models.

TrumpRx entered the market as a manufacturer‑driven coupon clearinghouse, positioning itself as a tool to lower out‑of‑pocket costs for consumers. By aggregating manufacturer coupons, the platform promises immediate price reductions at the point of sale, yet its design deliberately excludes Medicare, Medicaid, and other government‑funded plans, and prevents stacking with insurance benefits. These constraints raise questions about the program’s net impact on national drug expenditures, as savings may be confined to privately insured shoppers while leaving vulnerable populations untouched. Analysts suggest that without broader eligibility, TrumpRx may serve more as a marketing conduit for pharma firms than a substantive cost‑containment mechanism.

The American College of Physicians’ call to retire the word “provider” reflects a deeper concern about language shaping professional identity and patient trust. By distinguishing physicians from the broader “health care professional” cohort, ACP aims to reinforce the fiduciary duty inherent in the physician‑patient relationship, countering a trend toward commoditization of care. This semantic shift could influence electronic health record terminology, payer contracts, and legislative language, potentially strengthening accountability standards across the health system. As health policy increasingly emphasizes team‑based care, precise nomenclature will be essential to balance collaborative practice with clear responsibility for clinical outcomes.

Novo Nordisk sues Hims & Hers; TrumpRx is here; physicians are not ‘providers,’ says ACP – Morning Medical Update Weekly Recap

By Austin Littrell · February 13 2026

Key Takeaways

• Novo Nordisk’s action targets telehealth‑driven GLP‑1 compounding, asserting patent infringement, regulatory end‑runs, and patient deception following the FDA’s shortage resolution for semaglutide.

• Compounding demand surged during constrained Wegovy/Ozempic supply, but Novo frames continued compounded “semaglutide” sales as illegitimate now that supply has stabilized.

• TrumpRx operates as a manufacturer coupon clearinghouse; exclusions for government beneficiaries and limits on insurance stacking/deductible credit may blunt impact on net drug spend.

• ACP contends “provider” commoditizes physicians, recommending “physician” for MD/DO roles and “clinician/health care professional” for teams to preserve accountability and trust.

---

Why Novo Nordisk is suing Hims & Hers

Novo Nordisk alleges that Hims & Hers is illegally selling compounded versions of Wegovy and Ozempic after the U.S. Food and Drug Administration (FDA) declared semaglutide no longer in shortage. The lawsuit claims Hims’ products infringe Novo’s patents, bypass FDA safety review, and mislead patients by asserting they contain the same active ingredient as the branded drugs, even though Novo does not sell semaglutide for compounding. This is Novo’s first U.S. patent case targeting a large telehealth company over GLP‑1 compounding, aiming to curb a “wild‑west” market that expanded during the drug shortage but, Novo argues, should have ended once supply stabilized. [Reuters]

TrumpRx is live — it’s not exactly a government pharmacy

President Trump announced the launch of the TrumpRx website on February 5, positioning it as a step toward lowering U.S. drug prices through most‑favored‑nation pricing. The platform does not function as a federal direct‑to‑consumer pharmacy; instead, it provides manufacturer‑backed coupons that eligible Americans can redeem at retail pharmacies or through drugmakers’ own online fulfillment programs. Many offers exclude patients enrolled in government‑funded coverage, cannot be combined with insurance, and do not count toward deductibles. At launch, 43 medications were listed, despite 16 major pharmaceutical companies reportedly reaching pricing agreements with the administration. Whether the site will meaningfully reduce overall drug spending remains to be seen. [Pharmaceutical Executive]

Physicians are not ‘providers,’ says ACP

The American College of Physicians (ACP) argues that the term “provider” reduces physicians to interchangeable vendors and erodes the ethical, fiduciary nature of the physician‑patient relationship. In a new position paper, ACP recommends reserving “physician” for doctors and using “clinician” or “health care professional” for care teams, while avoiding “provider” altogether. The group emphasizes that language shapes how patients understand who is responsible for their care. [Read the full story]